Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 75/100

Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference

Key Takeaway: Insmed Incorporated announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. The presentation will showcase the company's commitment to developing innovative therapies for serious diseases. The event will be webcast live and archived for later access, highlighting Insmed's ongoing advancements in biopharmaceuticals.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is presenting at a prestigious healthcare conference.
  • The company is recognized as a top employer in the biopharmaceutical industry.
  • Insmed is advancing a diverse portfolio of innovative therapies.

Full Press Release Details

BRIDGEWATER, N.J.,Jan. 2, 2026/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.

This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website atwww.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1ScienceTop Employer. Visitwww.insmed.comto learn more or follow us onLinkedIn,Instagram,YouTube, andX.

Contact:

Investors:
Bryan DunnVice President, Investor Relations(646) 812-4030[email protected]
Media:
Claire MulhearnVice President, Corporate Communications(862) 842-6819[email protected]
SOURCE Insmed Incorporated

Frequently Asked Questions

When is Insmed's presentation at the J.P. Morgan Conference?

Insmed's presentation is scheduled for January 12, 2026, at 3:00 p.m. PT.

How can I access the Insmed presentation?

The presentation will be webcast live on Insmed's investor relations website.

What is Insmed's focus in biopharmaceuticals?

Insmed focuses on developing therapies for serious diseases, particularly pulmonary conditions.

Where is Insmed headquartered?

Insmed is headquartered in Bridgewater, New Jersey.

Last updated: Jan 2, 2026